InsidersTradesSigma
Total declarations
Companies
▲ Purchases (1 ops.)
▼ Sales (0 ops.)
Insider track record
Board DirectorDisclosed buys
1
Disclosed sells
0
T+90 hit rate
0%
T+90 mean return
-21.2%
Across 3 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Explore the detailed record of transactions filed by Hoberman Kenneth, Director. Insider active across 3 companies, notably TG Therapeutics, INC.. Aggregated, 9 disclosures have been logged. Breakdown: 1 buy · 0 sell. Total volume traded: €101k. Activity tracked since 18 June 2021. The latest transaction was disclosed on 19 June 2024 (Attribution). Regulator: SEC (Form 4). The full history is accessible without signup.
Declarations9 total
22,250 shares0Common StockSEC:0001437749-24-020849:0
30,000 shares0Common StockSEC:0001104659-24-071285:0
20,000 shares0Common StockSEC:0001104659-23-105394:0
18,000 shares0Common StockSEC:0001104659-23-072605:0
43,732 shares0Common StockSEC:0001104659-22-082020:0
6,000 shares@ US$17.400.034% mcap100.0% of flowCommon StockSEC:0001104659-22-060913:0
Ideal exit: 6 Feb 2023 (T+270)
20,000 shares0COMMON STOCKSEC:0001104659-21-084258
20,000 shares0COMMON STOCKSEC:0001104659-21-084258:0
150,000 sharesCommon StockSEC:0001104659-16-089212:0
9 of 9 declarations
About Hoberman Kenneth
Kenneth Hoberman is a Board Member at TG THERAPEUTICS, INC. and Nuvectis Pharma, Inc. With expertise in the biopharmaceutical sector, he oversees development and innovation strategies for these companies. His role is crucial in ensuring their success in the market.
